Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment

被引:40
作者
Drotar, DE [1 ]
Davis, EE [1 ]
Cockcroft, DW [1 ]
机构
[1] Royal Univ Hosp, Div Resp Med, Dept Med, Saskatoon, SK S7N 0W8, Canada
关键词
D O I
10.1016/S1081-1206(10)62935-3
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Regular use of salmeterol has been associated with reduced bronchoprotective effect against methacholine as early as 24 hours after initiating treatment. Objective: To determine whether loss of the bronchoprotective effect measured one hour after salmeterol could be demonstrated 12 hours following one previous dose. Methods: Ten subjects with stable, mild asthma were enrolled in a randomized, placebo-controlled, double-blind, crossover study comparing two 2-dose treatment periods: (1) blinded salmeterol 50 mu g inhaled at bedtime, followed by unblinded salmeterol 50 mu g inhaled 12 hours later and (2) blinded placebo inhaled at bedtime, followed by unblinded salmeterol 50 mu g inhaled 12 hours later. The methacholine PC20 was measured one hour after the morning salmeterol; FEV1 was measured just prior to the morning salmeterol dose and at the start of the methacholine inhalation test. Results: The mean log methacholine PC20 recorded one hour after a single dose of salmeterol (1.20 +/- 0.17 SE) was significantly higher than the mean log methacholine PC20, recorded after two doses of salmeterol at 12-hour intervals (1.00 +/- 0.16 SE; P = .024). The mean FEV1 12 hours after salmeterol was significantly higher than the mean FEV1 recorded 12 hours after placebo (P = .0017), however, there was no significant difference between the FEV1 recordings one hour after the two unblinded doses of salmeterol. Conclusions: Tolerance to the bronchoprotective effect of salmeterol against methacholine induced bronchoconstriction occurs extremely quickly as it is evident 12 hours after starting twice daily treatment.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 21 条
[1]   Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: Dose response [J].
Bhagat, R ;
Swystun, VA ;
Cockcroft, DW .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (01) :47-52
[2]   RAPID ONSET OF TOLERANCE TO THE BRONCHOPROTECTIVE EFFECT OF SALMETEROL [J].
BHAGAT, R ;
KALRA, S ;
SWYSTUN, VA ;
COCKCROFT, DW .
CHEST, 1995, 108 (05) :1235-1239
[3]   CHANGES IN METHACHOLINE-INDUCED BRONCHOCONSTRICTION WITH THE LONG-ACTING BETA(2) AGONIST SALMETEROL IN MILD-TO-MODERATE ASTHMATIC-PATIENTS [J].
BOOTH, H ;
FISHWICK, K ;
HARKAWAT, R ;
DEVEREUX, G ;
HENDRICK, DJ ;
WALTERS, EH .
THORAX, 1993, 48 (11) :1121-1124
[4]   LONG-ACTING VERSUS SHORT-ACTING BETA(2)-AGONISTS - IMPLICATIONS FOR DRUG-THERAPY [J].
BOULET, LP .
DRUGS, 1994, 47 (02) :207-222
[5]   LONG-TERM EFFECTS OF A LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSIVENESS IN PATIENTS WITH MILD ASTHMA [J].
CHEUNG, D ;
TIMMERS, MC ;
ZWINDERMAN, AH ;
BEL, EH ;
DIJKMAN, JH ;
STERK, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1198-1203
[6]   INTERACTION OF INHALED BETA(2) AGONIST AND INHALED CORTICOSTEROID ON AIRWAY RESPONSIVENESS TO ALLERGEN AND METHACHOLINE [J].
COCKCROFT, DW ;
SWYSTUN, VA ;
BHAGAT, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (05) :1485-1489
[7]   REGULAR USE OF INHALED ALBUTEROL AND THE ALLERGEN-INDUCED LATE ASTHMATIC RESPONSE [J].
COCKCROFT, DW ;
OBYRNE, PM ;
SWYSTUN, VA ;
BHAGAT, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 96 (01) :44-49
[8]   REGULAR INHALED SALBUTAMOL AND AIRWAY RESPONSIVENESS TO ALLERGEN [J].
COCKCROFT, DW ;
MCPARLAND, CP ;
BRITTO, SA ;
SWYSTUN, VA ;
RUTHERFORD, BC .
LANCET, 1993, 342 (8875) :833-837
[9]   Functional antagonism: Tolerance produced by inhaled beta(2) agonists [J].
Cockcroft, DW ;
Swystun, VA .
THORAX, 1996, 51 (10) :1051-1056
[10]   BRONCHIAL REACTIVITY TO INHALED HISTAMINE - METHOD AND CLINICAL SURVEY [J].
COCKCROFT, DW ;
KILLIAN, DN ;
MELLON, JJA ;
HARGREAVE, FE .
CLINICAL ALLERGY, 1977, 7 (03) :235-243